COMING SOON: Randomized Phase 3 Study of First-Line Selpercatinib Versus Pembrolizumab and Chemotherapy in RET Fusion-Positive Non-Small Cell Lung Cancer
Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.
Source: onclive.com